BIOMAT Database Logo BIOMAT Database Logo

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. 1991

M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Dipartimento di Medicina ed Oncologia sperimentale, Cattedra di Ematologia, Torino, Italy.

The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM). Three hundred four MM patients entered this study between March 1983 and July 1986; the analysis was performed in December 1989. The treatment groups did not show significant differences with respect to major prognostic factors. Median overall survival was 33.8 months. In the VMCP/VBAP and MP arms, after 12 induction chemotherapy cycles, 59.0% and 47.3% (P less than .068) of the patients achieved an M component reduction greater than 50%. No significant difference was observed in the two treatment arms in terms of remission duration (21.3 v 19.6 months, P less than .66) and survival (31.6 v 37.0 months, P less than .28). Patients younger than 65 years did not show any advantage from the alternating polychemotherapy. At diagnosis, the plasma cell labeling index (LI) and serum beta-2 microglobulin (beta 2-m) were evaluated in 173 and 183 patients, respectively. A significantly reduced survival was observed for patients with LI greater than or equal to 2% (16.4 months) or beta 2-m greater than or equal to 6 mg/L (20.4 months). Even in these poor-risk subgroups, VMCP/VBAP was not superior to MP.

UI MeSH Term Description Entries
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
July 1989, European journal of haematology,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
June 1990, Blut,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
June 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Combination chemotherapy versus melphalan and prednisone in multiple myeloma.
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
January 1984, The Netherlands journal of medicine,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
[Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
May 1984, Revue du rhumatisme et des maladies osteo-articulaires,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
January 1980, Cancer treatment reports,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
January 1985, Oncology,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
March 2016, Blood,
M Boccadoro, and F Marmont, and M Tribalto, and G Avvisati, and A Andriani, and T Barbui, and M Cantonetti, and M Carotenuto, and B Comotti, and F Dammacco
High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma.
September 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!